Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Open in API
Filings indexed 1,027 across all filing types
Latest filing 2024-11-05 Director's Dealing
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-11-05 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a private placement of common stock, registration rights agreement, exchange transactions, convertible notes conversion, voting results from the 2024 Annual Meeting of Stockholders, and Nasdaq listing compliance matters. The document is not a full annual or quarterly report, nor is it a transcript or presentation. It primarily reports on financing activities, stock issuance, and shareholder voting results. The key focus is on capital raising and related agreements, as well as voting outcomes related to these transactions. Therefore, the document fits best under Capital/Financing Update (CAP) due to the detailed description of private placements, convertible notes, and stock issuance. The voting results are part of the report but do not dominate the content to classify it as Declaration of Voting Results (DVA). The length and detail confirm it is not a brief announcement or a simple voting result notice but a comprehensive current report on financing and related corporate actions.
2024-10-29 English
Annual Report 2024
Annual Report
2024-10-16 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement
2024-10-07 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header 'SCHEDULE 14A INFORMATION' and the title 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is for the 2024 Annual Meeting of Stockholders of Eterna Therapeutics Inc. The content includes detailed information about the meeting, proposals to be voted on (election of directors, ratification of auditors, stock issuance), voting instructions, and other governance-related information. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is not an announcement of voting results (DVA), nor is it the actual Annual Report (10-K) or other financial report. Therefore, the correct classification is PSI with high confidence.
2024-09-27 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (an Exclusive License and Collaboration Agreement) and termination of a prior agreement. It includes details about the agreement terms, payments, and references that the full agreement will be filed as an exhibit to the upcoming 10-Q quarterly report. There are no financial statements or comprehensive financial data presented here, only a description of a material contract event. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Capital/Financing Update or M&A Activity since it is about a licensing agreement. The document length is over 5,000 characters and contains substantive information about the event, not just a brief announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.